Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster ...

Novo Nordisk (NYSE: NVO) announced Thursday it will initiate Phase 3 trials for its experimental weight-loss drug amycretin in both injection and oral forms during the first quarter of 2026. The ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

The Shapiro administration's plan would limit Ozempic access under Medicaid to save costs. Not everyone is on board.